The Pharma Data

JANUARY 25, 2021

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 27, 2021

3.375% Notes due 2029 532457 BV9 12 1.250% due August 15, 2031 1.321% 15 bps $1,130.16 and Citigroup Global Markets Inc. Treasury Security Reference Yield Fixed Spread Total Consideration (1)(2) 4.150% Notes due 2059 532457 BU1 1 (3) 2.375% due May 15, 2051 1.865% 80 bps $1,347.88 Lilly has retained BofA Securities, Inc.

Disease 52

Disease Marketing 52

The Pharma Data

SEPTEMBER 7, 2021

3.375% Notes due 2029. and Citigroup Global Markets Inc. toll-free at +1 (888) 292-0070 or collect at +1 (980) 387-3907 or to Citigroup Global Markets Inc. 360,745,000. 1.750% due August 15, 2041. 3.700% Notes due 2045. 532457 BJ6. 412,467,000. 2.375% due May 15, 2051. 532457 BV9. 1,150,000,000. 1.250% due August 15, 2031.

Licensing 52

Licensing Licensing Marketing 52

The Pharma Data

SEPTEMBER 27, 2021

and Citigroup Global Markets Inc. toll-free at +1 (888) 292-0070 or collect at +1 (980) 387-3907 or to Citigroup Global Markets Inc. As a result, tendered notes may not be withdrawn, except in certain limited circumstances where additional withdrawal rights are required by law. Lilly has retained BofA Securities, Inc.

Marketing 40

Marketing Disease 40

Agency IQ

JANUARY 26, 2024

MDR Article 78(14) sets out the original transition deadline in going from voluntary use of the coordinated assessment process to mandatory use as May 25, 2027; for IVDs, use of the coordinated procedure becomes mandatory in May 26, 2029 for all Member States, as set out in IVDR Article 74(14).

Regulations 40

Regulations Compliance Laboratories Production 40

Agency IQ

NOVEMBER 27, 2023

BY RAYAN BHARGAVA, MSC | NOV 17, 2023 4:53 PM CST Regulatory background The European Partnership for the Assessment of Risks from Chemicals (PARC) is the seven year program, lasting from 2022 to 2029, which aims to facilitate, share, and improve research on chemical risk assessment.

Animal Testing 40

Animal Testing Research Regulations Compliance 40

Agency IQ

FEBRUARY 2, 2024

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. IVDs used in blood donation screening/processing). In the E.U.,

FDA 40

FDA Laboratories Regulations Production 40

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

H1 Blog

MARCH 28, 2023

In fact, the global medical devices market is projected to grow from $495.46 billion by 2029. Understanding and incorporating the payer perspective and data requirements early in product development is essential in this increasingly cost-conscious market. billion in 2022 to $718.92

Production 52

Production Marketing Hospitals Treatment 52

The Pharma Data

MARCH 31, 2022

650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. The transaction has been led by Morgan Stanley and Natixis CIB as Global Coordinators & Sustainability-Linked Structuring Advisors and, Barclays, MUFG and RBC Capital Markets, all as Joint Active Bookrunners.

Treatment 52

Treatment Government Vaccine Disease 52

Vial

MARCH 1, 2024

By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

Policy Prescription

MARCH 26, 2021

CBO looked at what would happen to the drug price market if elements of the Lower Drug Prices Now Act of 2019 (H.R. The savings to the government would be about $345 billion between 2023-2029 because of lower prices. The Congressional Budget Office’s analysis finds that there will be tradeoffs. 3) were implemented.

Drugs 52

Drugs Government Vaccine Pharmaceuticals 52

Perficient: Drug Development

APRIL 18, 2025

Educate Your Team Hold knowledge-sharing sessions with developers, infrastructure engineers, and marketers Make sure everyone understands the impact of expired certificates on the Sitecore experience 6.

Engineering 52

Engineering Production Marketing International 52

Codon

FEBRUARY 23, 2025

million new HIV infections by 2029, undermining progress toward the UN’s goal. Pharmaceutical companies generally charge high rates for patented drugs to recoup their huge investments into research, development, trials, and marketing. By February, the U.S. In South Africa, there are about 150,000 new HIV infections each year.

Clinical Trials 82

Clinical Trials Virus Vaccine DNA 82